Abstract
Acute kidney injury (AKI) is a common and potentially life-threatening complication after ischemia/reperfusion and exposure to nephrotoxic agents. In this study, we examined the efficacy and mechanism(s) of suramin in promoting recovery from glycerol-induced AKI, a model of rhabdomyolysis-induced AKI. After intramuscular glycerol injection (10 ml of 50% glycerol per kilogram) into male Sprague-Dawley rats, serum creatinine maximally increased at 24 to 72 h and then decreased at 120 h. Creatinine clearance (CrCl) decreased 75% at 24 to 72 h and increased at 120 h. Suramin (1 mg/kg i.v.) administered 24 h after glycerol accelerated recovery of renal function as demonstrated by increased CrCl, decreased renal kidney injury molecule-1, and improved histopathology 72 h after glycerol injection. Suramin treatment decreased interleukin-1β (IL-1β) mRNA, transforming growth factor-β1 (TGF-β1), phospho-p65 of nuclear factor-κB (NF-κB), and cleaved caspase-3 at 48 h compared with glycerol alone. Suramin treatment also decreased glycerol-induced activation of intracellular adhesion molecule-1 (ICAM-1) and leukocyte infiltration at 72 h. Urinary/renal neutrophil gelatinase-associated lipocalin 2 (NGAL) levels, hemeoxygenase-1 expression, and renal cell proliferation were increased by suramin compared with glycerol alone at 72 h. Mechanistically, suramin decreases early glycerol-induced proinflammatory (IL-1β and NF-κB) and growth inhibitory (TGF-β1) mediators, resulting in the prevention of late downstream inflammatory effects (ICAM-1 and leukocyte infiltration) and increasing compensatory nephrogenic repair. These results support the hypothesis that delayed administration of suramin is effective in abrogating apoptosis, attenuating inflammation, and enhancing nephrogenic repair after glycerol-induced AKI.
Footnotes
This study was supported by National Institutes of Health National Institute of General Medical Sciences [Grant GM084147]; and the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. Animal facilities were funded by National Institutes of Health National Center for Research Resources [Grant C06-RR015455]. This publication (or project) was also supported by the South Carolina Clinical & Translational Research Institute, with an academic home at the Medical University of South Carolina, National Institutes of Health National Center for Research Resources [Grant UL1-RR029882].
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the National Center for Research Resources.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
ABBREVIATIONS:
- AKI
- acute kidney injury
- CrCl
- creatinine clearance
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase
- HO-1
- hemeoxygenase-1
- IL
- interleukin
- ICAM-1
- intracellular adhesion molecule-1
- I/R
- ischemia/reperfusion
- KIM-1
- kidney injury molecule-1
- MCP-1
- monocyte chemoattractant protein-1
- NF-κB
- nuclear factor κB
- NGAL
- neutrophil gelatinase-associated lipocalin 2
- OSOM
- outer stripe of the outer medulla
- PCNA
- proliferating cell nuclear antigen
- TGF-β1
- transforming growth factor-β1
- TNF-α
- tumor necrosis factor-α.
- Received November 29, 2011.
- Accepted January 6, 2012.
- U.S. Government work not protected by U.S. copyright
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|